Antimalarial drugs - host targets (re)visited

Area of Science:

• Malariology
• Drug Discovery
• Molecular Biology

Background:

• Malaria remains a significant global health threat, with 40% of the world's population at risk annually.
• Plasmodium falciparum's drug resistance and lack of an effective vaccine highlight the urgent need for new antimalarial therapies.
• Existing treatments face challenges due to evolving drug resistance, necessitating continuous research into novel compounds and strategies.

Purpose of the Study:

• To review current antimalarial drugs, mechanisms of resistance, and combination strategies.
• To explore novel anti-plasmodial compounds and drug targets.
• To emphasize the potential of host genes and molecules as targets for new antimalarial drugs.

Main Methods:

• Literature review of existing antimalarial research.
• Analysis of drug resistance mechanisms in Plasmodium falciparum.
• Investigation of host-pathogen interactions, specifically Hepatocyte Growth Factor/MET signaling in hepatocytes.

Main Results:

• Hepatocyte Growth Factor/MET signaling was identified as essential for malaria parasite establishment in hepatocytes.
• This pathway presents a novel target for antimalarial drug development.
• The study highlights the potential for host-directed therapies in malaria prophylaxis.

Conclusions:

• Novel antimalarial drugs are crucial due to widespread drug resistance.
• Host pathways, such as Hepatocyte Growth Factor/MET signaling, offer promising new targets for therapeutic intervention.
• Targeting host molecules could provide a strategy for malaria prophylaxis and treatment.